
The CHMP has Adopted a Negative Opinion for Omburtamab for the Treatment of CNS/LM Metastasis from Neuroblastoma in Europe 16 December 2022
NEW YORK, Dec. 16, 2022 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
NEW YORK, Dec. 16, 2022 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
Formand for Trial Nation Thomas Kongstad Petersen havde gerne set, at SVM-regeringen havde finansieringen... Read more
Copenhagen, Denmark, 15 December 2022 – MinervaX ApS, a privately held Danish biotechnology company... Read more
NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
Oslo Norway, November 18, 2022. The LINK Medical Board is pleased to announce the appointment of Sissel... Read more
ViroGates announces the emergency use authorisation of Kineret treatment for COVID-19 related pneumonia... Read more